<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The global polycystic kidney disease (PKD) market is expanding rapidly due to rising prevalence, advanced treatments, and increased awareness. The growing cases of chronic kidney diseases (CKD) including PKD, driven by factors like genetic mutations, hypertension, and diabetes, contribute to the market's growth. Innovations in diagnostics, such as MRI and genetic testing, facilitate early intervention in PKD cases. The approval of tolvaptan and ongoing research into therapies like lixivaptan offer potential breakthroughs. North America leads the market, supported by robust healthcare infrastructure, while Asia-Pacific sees significant growth. Key players include Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals, shaping a competitive landscape focused on personalized medicine.Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6233856/polycystic-kidney-disease-market-global?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9q7z6t&amp;utm_campaign=2259282+-+Polycystic+Kidney+Disease+Market+Analysis+Report+2026-2036%2c+Profiles+of+Key+Players+-+Otsuka+Pharmaceutical%2c+Novartis%2c+Pfizer%2c+and+Vertex+Pharmaceuticals&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Polycystic Kidney Disease Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, 2026-2036">"Polycystic Kidney Disease Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, 2026-2036"</a> report has been added to ResearchAndMarkets.com's offering. The global polycystic kidney disease (PKD) market is experiencing significant growth, driven by increasing prevalence, advancements in treatment options, and heightened awareness. The rising prevalence of chronic kidney diseases (CKD), including PKD, is a significant contributor to the market's expansion. Factors such as genetic mutations, hypertension, and diabetes exacerbate the condition, leading to a higher incidence of end-stage renal disease (ESRD) and increased demand for treatment options. Moreover, enhanced diagnostic methods, including contrast-enhanced ultrasonography (CEUS), magnetic resonance imaging (MRI), and genetic testing, have improved early detection and monitoring of PKD. These advancements facilitate timely interventions, potentially slowing disease progression and improving patient outcomes. Furthermore, the approval of tolvaptan, the first FDA-approved drug for ADPKD, marked a significant milestone in PKD treatment. Ongoing research and clinical trials are exploring additional therapies, such as lixivaptan and tesevatinib, which aim to address the underlying causes of PKD and offer potential benefits over existing treatments. In addition, the rising awareness about PKD's genetic nature has led to more families undergoing genetic screening and early detection. Early treatment can help preserve kidney function longer, reducing the risk of progression to ESRD. The development of targeted therapies also offers promising avenues for treating PKD. Emerging treatments aim to address the underlying mechanisms of cyst formation and kidney damage, potentially slowing disease progression and improving patient outcomes. For instance, novel pharmacological agents targeting specific pathways involved in cystogenesis are under investigation, with some showing early signs of efficacy in clinical trials. The shift towards personalized or precision medicine in PKD involves tailoring treatment strategies based on individual genetic profiles, disease progression, and response to therapy. This approach aims to optimize treatment efficacy and minimize adverse effects, ensuring that patients receive the most appropriate care for their specific condition. The PKD landscape is ripe with opportunities across various domains, including therapeutic advancements, personalized care, market expansion, and collaborative efforts. Stakeholders who can leverage these opportunities are well-positioned to make significant contributions to the management and treatment of PKD. North America, particularly the U.S., holds a dominant position in the global PKD market. This leadership is attributed to advanced healthcare infrastructure, high healthcare expenditure, and a robust regulatory environment that supports the development and approval of new treatments. The U.S. Food and Drug Administration's approval of tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) has significantly impacted the market, providing a disease-modifying therapy that slows kidney function decline. Additionally, the presence of major pharmaceutical companies and ongoing research initiatives further bolster the market's growth in this region. The Asia-Pacific region is experiencing the highest growth in the PKD market, driven by increasing healthcare investments, rising awareness, and a large patient population. Countries such as China, Japan, and India are making significant strides in improving healthcare infrastructure and diagnostic capabilities. For instance, Japan has been at the forefront of genetic research into ADPKD, leading to region-specific treatment guidelines. However, challenges like healthcare disparities and limited access to advanced therapies in rural areas persist, which may affect the equitable distribution of treatment benefits. The competitive landscape of the polycystic kidney disease (PKD) market is shaped by an intersection of established pharmaceutical companies, innovative biotech firms, and a growing focus on personalized, precision medicine. The market is experiencing dynamic growth as new treatments and therapies are developed to manage and slow the progression of the disease, particularly in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Key players in this landscape include Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals, each contributing to the development of cutting-edge therapies aimed at treating PKD. Key Topics Covered: Executive Summary Scope and Definition Market/Product Definition Key Questions Answered Analysis and Forecast Note 1. Global Polycystic Kidney Disease Market: Industry Outlook 1.1 Industry Outlook 1.1.1 Market Introduction 1.1.2 Epidemiological Analysis of Polycystic Kidney Disease Market 1.1.3 Introduction on Polycystic Kidney Disease Market 1.2 Pipeline Analysis 1.3 Treatment Landscape 1.4 Regulatory Landscape of Polycystic Kidney Disease Market 1.4.1 Legal Requirement and Framework in the U.S. 1.4.2 Legal Requirement and Framework in the E.U. 1.4.3 Legal Requirement and Framework in Japan 1.4.4 Legal Requirement and Framework in Rest-of-the-World 1.5 Market Dynamics 1.5.1 Impact Analysis 1.5.2 Market Drivers 1.5.3 Market Restraint 1.5.4 Market Opportunities 2. Global Polycystic Kidney Disease Market (By Disease Type), $Million, 2025-2036 2.1 Overview 2.2 Autosomal Dominant Form 2.3 Autosomal Recessive Form 2.4 Familial Nephronophthisis 2.5 Medullary Cystic Kidney Disease 3. Global Polycystic Kidney Disease Market (By Treatment), $Million, 2025-2036 3.1 Overview 3.2 Pharmacological 3.2.1 RAS Inhibitors 3.2.2 Tyrosine Kinase Inhibitors 3.2.3 Other Drugs 3.3 Non-Pharmacological 3.3.1 Surgical Treatment 3.3.2 Supportive Therapies 4. Global Polycystic Kidney Disease Market, by Region, $Million, 2025-2036 4.1 Overview 4.2 North America 4.2.1 Business Drivers 4.2.2 Business Challenges 4.2.3 Market Sizing and Forecast 4.2.3.1 North America Polycystic Kidney Disease Market, by Country 4.2.3.1.1 U.S. 4.2.3.1.2 Canada 4.3 Europe 4.3.1 Business Drivers 4.3.2 Business Challenges 4.3.3 Market Sizing and Forecast 4.3.3.1 Europe Polycystic Kidney Disease Market, by Country 4.3.3.1.1 Germany 4.3.3.1.2 U.K. 4.3.3.1.3 France 4.3.3.1.4 Italy 4.3.3.1.5 Spain 4.3.3.1.6 Rest-of-Europe 4.4 Asia-Pacific 4.4.1 Business Drivers 4.4.2 Business Challenges 4.4.3 Market Sizing and Forecast 4.4.3.1 Asia-Pacific Polycystic Kidney Disease Market, by Country 4.4.3.1.1 Japan 4.4.3.1.2 China 4.4.3.1.3 India 4.4.3.1.4 Australia 4.4.3.1.5 South Korea 4.4.3.1.6 Rest-of-APAC 4.5 Rest-of-the-world 4.5.1 Business Drivers 4.5.2 Business Challenges 4.5.3 Market Sizing and Forecast 5. Competitive Landscape and Company Profiles 5.1 Competitive Landscape 5.1.1 Overview 5.1.2 Key Developments and Strategies 5.1.2.1 Funding Activities 5.1.2.2 Mergers and Acquisitions 5.1.2.3 Regulatory Approvals 5.1.2.4 Partnerships, Collaborations and Business Expansions 5.1.3 Growth-Share Analysis (by Company) 5.2 Company Profiles 5.2.1 Overview 5.2.2 Product Portfolio 5.2.3 Target Customers 5.2.4 Key Personnel 5.2.5 Analyst View <ul><li>Ostuka Pharmaceuticals Co. Ltd.</li><li>AbbVie, Inc.</li><li>Eli Lily and Company</li><li>Bayer AG</li><li>Novartis AG</li><li>Vertex Pharmaceuticals</li><li>Galapagos NV</li><li>Johnson and Johnson</li><li>Reata Pharmaceuticals</li><li>Renasant Bio</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6233856/polycystic-kidney-disease-market-global?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9q7z6t&amp;utm_campaign=2259282+-+Polycystic+Kidney+Disease+Market+Analysis+Report+2026-2036%2c+Profiles+of+Key+Players+-+Otsuka+Pharmaceutical%2c+Novartis%2c+Pfizer%2c+and+Vertex+Pharmaceuticals&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/65x033</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YzdkMTU2NDYtYTkyMS00ZGExLWE0NDgtNmIwYTRhOGFiMDQ4LTEwMjY3MzctMjAyNi0wNS0yMS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Polycystic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn